Global Hereditary Angioedema Drug Market (Sales, Revenue, Price, Gross Profit and Competitors Analysis of Major Market) from 2015-2026
- Published Date: 2021-01-17
- Report ID: 38517
- Pages: 109
-
Format:
Summary
As the world continues to deal with COVID-19, economies are moving into recession, under multiple adverse factors, the GDP of European and American countries in the second quarter suffered a historical contraction. At an annualized rate, the US GDP fell by 32.9% month on month, while the overall GDP of the euro zone fell by 12.1%.
Moreover, the economic prospects of Europe and the United States in the third quarter under the epidemic situation are hardly optimistic. The resumption of work and production not only brought economic data back, but also triggered a rebound in the epidemic situation. At present, the United States is still the 'epicenter' of the global epidemic. The total number of confirmed cases has exceeded 4.8 million, and the epidemic situation in some European countries has also rebounded. Affected by this, more than 20 states in the United States have announced the suspension or withdrawal of part of the economic restart plan. Britain and Italy have also decided to extend the state of emergency. The rebound of the epidemic situation has posed considerable risks to the economic prospects of Europe and the United States.
In the second quarter of this year, US GDP shrank by 9.5% on a month on month basis, or 32.9% at an annual rate, the largest decline since the 1940s. Data show that the sharp decline in personal consumption is the main drag on the U.S. GDP growth in the second quarter.
Compared with the United States, Europe's economic contraction in the second quarter was smaller, but it was also the lowest on record, with Germany and France contracting more than 10%. According to the data released by the Federal Bureau of statistics, Germany's GDP fell by 10.1% in the second quarter after adjusting for prices, seasons and working days, the largest decline since the quarterly economic data were available in 1970.
Thanks to the effective control and policy support of the new epidemic, China's economy rebounded sharply in the second quarter. The growth rate of manufacturing industry, which accounted for about 28% of GDP, rebounded sharply to 4.4% from the negative value in the first quarter. Chinese original equipment manufacturers (OEMs) and suppliers are ramping up production. And there are increased investments in digital footprints in manufacturing. OEMs in other parts of the world are offering incentives to drive sales. Prudent Markets published a report for global Hereditary Angioedema Drug market in this environment.
In terms of revenue, this research report indicated that the global Hereditary Angioedema Drug market was valued at USD XXX million in 2019, and it is expected to reach a value of USD XXX million by 2026, at a CAGR of XX % over the forecast period 2021-2026. Correspondingly, the forecast analysis of Hereditary Angioedema Drug industry comprises of China, USA, Japan, India, Korea and South America, with the production and revenue data in each of the sub-segments.
The Pharming Group NV aims at producing XX Hereditary Angioedema Drug in 2020, with XX % production to take place in global market, Takeda accounts for a volume share of XX %.
Regional Segmentation (Value; Revenue, USD Million, 2015 - 2026) of Hereditary Angioedema Drug Market by Prudent Markets Include
China
EU
USA
Japan
India
Southeast Asia
South America
Competitive Analysis; Who are the Major Players in Hereditary Angioedema Drug Market
Pharming Group NV
Takeda
CSL Limited
IBio Inc.
BioCryst Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc.
...
Major Type of Hereditary Angioedema Drug Covered in Prudent Markets report:
C1 Esterase Inhibitor
Kallikrein Inhibitor
Selective Bradykinin B2 Receptor Antagonist
Application Segments Covered in Prudent Markets Market
Retail Pharmacies
Hospital Pharmacies
Online Pharmacies
For any other requirements, please feel free to contact us and we will provide you customized report.
Table of Contents
Global Hereditary Angioedema Drug Market Analysis 2020, With Top Companies, Production, Revenue, Consumption, Price and Growth Rate
1 Market Scope
1.1 Product Details and Introduction
1.1.1 C1 Esterase Inhibitor -Product Introduction and Major Manufacturers
1.1.2 Kallikrein Inhibitor -Product Introduction and Major Manufacturers
1.1.3 Selective Bradykinin B2 Receptor Antagonist -Product Introduction and Major Manufacturers
1.2 Market Snapshot
1.2.1 Major Companies Overview
1.2.2 Market Concentration
1.2.3 Six-Year Compound Annual Growth Rate (CAGR)
2 Global Hereditary Angioedema Drug Market Assessment, by Segmentation
2.1 Type Breakdown Estimates & Forecast, Sales Volume (2015-2026)
2.2 Type Breakdown Estimates & Forecast, Sales Value (2015-2026)
2.3 Application Breakdown Estimates & Forecast, by Application (2015-2026)
3 Regional Market Analysis
3.1 China Hereditary Angioedema Drug Market
3.1.1 Top Companies leading Hereditary Angioedema Drug Development in China (2015-2020)
3.1.2 Sales Value of Major Company in China Market (2015-2020)
3.1.3 China Hereditary Angioedema Drug Price (USD/Unit), by Type (2019-2020)
3.1.4 Sales in China Market, by Type (2015-2026)
3.2 EU Hereditary Angioedema Drug Market
3.2.1 Top Companies leading Hereditary Angioedema Drug Development in EU (2015-2020)
3.2.2 Sales Value of Major Company in EU Market (2015-2020)
3.2.3 EU Hereditary Angioedema Drug Price (USD/Unit), by Type (2019-2020)
3.2.4 Sales in EU Market, by Type (2015-2026)
3.3 USA Hereditary Angioedema Drug Market
3.3.1 Top Companies leading Hereditary Angioedema Drug Development in USA (2015-2020)
3.3.2 Sales Value of Major Company in USA Market (2015-2020)
3.3.3 USA Hereditary Angioedema Drug Price (USD/Unit), by Type (2019-2020)
3.3.4 Sales in USA Market, by Type (2015-2026)
3.4 Japan Hereditary Angioedema Drug Market
3.4.1 Top Companies leading Hereditary Angioedema Drug Development in Japan (2015-2020)
3.4.2 Sales Value of Major Company in Japan Market (2015-2020)
3.4.3 Japan Hereditary Angioedema Drug Price (USD/Unit), by Type (2019-2020)
3.4.4 Sales in Japan Market, by Type (2015-2026)
3.5 India Hereditary Angioedema Drug Market
3.5.1 Top Companies leading Hereditary Angioedema Drug Development in India (2015-2020)
3.5.2 Sales Value of Major Company in India Market (2015-2020)
3.5.3 India Hereditary Angioedema Drug Price (USD/Unit), by Type (2019-2020)
3.5.4 Sales in India Market, by Type (2015-2026)
3.6 Southeast Asia Hereditary Angioedema Drug Market
3.6.1 Top Companies leading Hereditary Angioedema Drug Development in Southeast Asia (2015-2020)
3.6.2 Sales Value of Major Company in Southeast Asia Market (2015-2020)
3.6.3 Southeast Asia Hereditary Angioedema Drug Price (USD/Unit), by Type (2019-2020)
3.6.4 Sales in Southeast Asia Market, by Type (2015-2026)
3.7 South America Hereditary Angioedema Drug Market
3.7.1 Top Companies leading Hereditary Angioedema Drug Development in South America (2015-2020)
3.7.2 Sales Value of Major Company in South America Market (2015-2020)
3.7.3 South America Hereditary Angioedema Drug Price (USD/Unit), by Type (2019-2020)
3.7.4 Sales in South America Market, by Type (2015-2026)
4 Value Chain (Impact of COVID-19)
4.1 Hereditary Angioedema Drug Value Chain Analysis
4.1.1 Upstream
4.1.2 Downstream
4.2 COVID-19 Impact on Hereditary Angioedema Drug Industry
4.2.1 Industrial Policy Issued Under the Epidemic Situation
4.3 Cost-Under the Epidemic Situation
4.3.1 Cost of Raw Material
4.4 Channel Analysis
4.4.1 Distribution Channel-Under the Epidemic Situation
4.4.2 Distributors
5 Regional Market Forecast (2021-2026)
5.1 Global Hereditary Angioedema Drug Sales and Growth Rate (2021-2026)
5.2 Global Hereditary Angioedema Drug Sales Value and Growth Rate (2021-2026)
6 Hereditary Angioedema Drug Competitive Analysis
6.1 Pharming Group NV
6.1.1 Pharming Group NV Company Profiles
6.1.2 Pharming Group NV Product Introduction
6.1.3 Pharming Group NV Hereditary Angioedema Drug Production, Revenue (2015-2020)
6.1.4 SWOT Analysis
6.2 Takeda
6.2.1 Takeda Company Profiles
6.2.2 Takeda Product Introduction
6.2.3 Takeda Hereditary Angioedema Drug Production, Revenue (2015-2020)
6.2.4 SWOT Analysis
6.3 CSL Limited
6.3.1 CSL Limited Company Profiles
6.3.2 CSL Limited Product Introduction
6.3.3 CSL Limited Hereditary Angioedema Drug Production, Revenue (2015-2020)
6.3.4 SWOT Analysis
6.4 IBio Inc.
6.4.1 IBio Inc. Company Profiles
6.4.2 IBio Inc. Product Introduction
6.4.3 IBio Inc. Hereditary Angioedema Drug Production, Revenue (2015-2020)
6.4.4 SWOT Analysis
6.5 BioCryst Pharmaceuticals, Inc.
6.5.1 BioCryst Pharmaceuticals, Inc. Company Profiles
6.5.2 BioCryst Pharmaceuticals, Inc. Product Introduction
6.5.3 BioCryst Pharmaceuticals, Inc. Hereditary Angioedema Drug Production, Revenue (2015-2020)
6.5.4 SWOT Analysis
6.6 Ionis Pharmaceuticals, Inc.
6.6.1 Ionis Pharmaceuticals, Inc. Company Profiles
6.6.2 Ionis Pharmaceuticals, Inc. Product Introduction
6.6.3 Ionis Pharmaceuticals, Inc. Hereditary Angioedema Drug Production, Revenue (2015-2020)
6.6.4 SWOT Analysis
7 Conclusion
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
